<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ginsberg, Henry N.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Results from the ACCORD Lipid Study</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-11</style></pages><abstract><style  face="normal" font="default" size="100%">The Action to Control Cardiovascular Risk in Diabetes [ACCORD] Lipid study [NCT00000620] does not support the use of combination fibrate and statin therapy compared with statin therapy alone to reduce cardiovascular risk in high-risk patients with type 2 diabetes mellitus. However, subgroup analyses suggest a treatment interaction that is associated with combination therapy and gender and a possible interaction between combination therapy and severe dyslipidemia.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>